¿Qué esperar de la vacuna de Covid-19?

26 de Noviembre de 2024

¿Qué esperar de la vacuna de Covid-19?

FRANCE-HEALTH-VIRUS-MODERNA-VACCINE

This creative image taken in a studio in Paris on November 16, 2020, showing a syringe and a vaccine vial with the reproducted logo of a US biotech firm Moderna, illustrates the announcement of an experimental vaccine against Covid-19 from Moderna that would be nearly 95% effective, marking a second major step forward in the quest to end the Covid-19 pandemic. (Photo by JOEL SAGET / AFP) / �The erroneous mention[s] appearing in the metadata of this photo by JOEL SAGET has been modified in AFP systems in the following manner: [This creative image taken in a studio in Paris on November 16, 2020, showing a syringe and a vaccine vial with the reproducted logo of a US biotech firm Moderna, illustrates the announcement of an experimental vaccine against Covid-19 from Moderna that would be nearly 95% effective, marking a second major step forward in the quest to end the Covid-19 pandemic.] instead of [This illustration picture taken in a studio in Paris on November 16, 2020, shows a syringe and a vial with the logo of US biotech firm Moderna.]. Please immediately remove the erroneous mention[s] from all your online services and delete it (them) from your servers. If you have been authorized by AFP to distribute it (them) to third parties, please ensure that the same actions are carried out by them. Failure to promptly comply with these instructions will entail liability on your part for any continued or post notification usage. Therefore we thank you very much for all your attention and prompt action. We are sorry for the inconvenience this notification may cause and remain at your disposal for any further information you may require.�

/

JOEL SAGET/AFP

This creative image taken in a studio in Paris on November 16, 2020, showing a syringe and a vaccine vial with the reproducted logo of a US biotech firm Moderna, illustrates the announcement of an experimental vaccine against Covid-19 from Moderna that would be nearly 95% effective, marking a second major step forward in the quest to end the Covid-19 pandemic. (Photo by JOEL SAGET / AFP) / “The erroneous mention[s] appearing in the metadata of this photo by JOEL SAGET has been modified in AFP systems in the following manner: [This creative image taken in a studio in Paris on November 16, 2020, showing a syringe and a vaccine vial with the reproducted logo of a US biotech firm Moderna, illustrates the announcement of an experimental vaccine against Covid-19 from Moderna that would be nearly 95% effective, marking a second major step forward in the quest to end the Covid-19 pandemic.] instead of [This illustration picture taken in a studio in Paris on November 16, 2020, shows a syringe and a vial with the logo of US biotech firm Moderna.]. Please immediately remove the erroneous mention[s] from all your online services and delete it (them) from your servers. If you have been authorized by AFP to distribute it (them) to third parties, please ensure that the same actions are carried out by them. Failure to promptly comply with these instructions will entail liability on your part for any continued or post notification usage. Therefore we thank you very much for all your attention and prompt action. We are sorry for the inconvenience this notification may cause and remain at your disposal for any further information you may require.”
Foto: AFP

Ricardo Cortés Alcalá, titular de la Dirección General de Promoción de la Salud, señaló que existen dos caminos que esperar sobre la vacuna

Los anuncios de la eficiencia en las vacunas de Covid-19 de laboratorios como Pfizer, Moderna y la desarrollada por Rusia han puesto de buen ánimo a los mercados, sin embargo la Organización Mundial de la Salud (OMS) ha preferido ser cautelosa.

Ricardo Cortés Alcalá, titular de la Dirección General de Promoción de la Salud, explicó que esa reserva se debe a que aún no se sabe cómo se comportarán las vacunas en condiciones reales.

“No sabemos realmente cuál va a ser el comportamiento de cualquiera de las vacunas que se metan a todo el mundo y no sólo en la población en la que se analizó esté 94 por ciento”, dijo Cortés Alcalá al referirse a la vacuna de Moderna.

El doctor señaló que existen dos caminos que esperar sobre la vacuna. El primero es que alguna de ellas o todas las que se desarrollen, corten de tajo las cadenas de contagio y con ello se podría erradicar la enfermedad.

Así ocurre por ejemplo con las vacunas de sarampión o viruela, que dotan de inmunidad al organismo. Entonces la vacunación sería la vía para eliminar la Covid-19.

Sin embargo, alguna o todas las vacunas podrían tener otro tipo de comportamiento, que no sería la inmunidad, sino evitar que las poblaciones en riesgo desarrollen la forma grave del SARS-CoV-2.

Sería muy bueno “al menos tener una vacuna que nos proteja lo suficiente y sobre todo a las personas con mayor probabilidad de tener un cuadro grave”, dijo Cortés Alcalá.

Si la o las vacunas se comportan de la segunda forma, que sería muy similar a la forma en la que actúa la vacuna contra la influenza, el número de contagios no se vería disminuido de forma acelerada, pero las tasas de víctimas mortales de la enfermedad si decaerían.

Con datos reportados hasta este lunes, en México suman un millón 9 mil 396 contagios y 98 mil 861 decesos. NR

https://twitter.com/EjeCentral/status/1328506094809919489?s=20

ES DE INTERÉS |

Vacuna no bastará para vencer al virus: OMS

Moderna anuncia que su vacuna antiCovid tiene eficacia de 94.5%

Vacuna “Sputnik V” demuestra eficacia del 92%

Pfizer afirma que su vacuna contra Covid-19 es ‘eficaz en un 90%'